The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | SOUNDTRACK-F1: surovatamig plus rituximab vs chemotherapy plus rituximab in previously untreated FL
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, briefly introduces the SOUNDTRACK-F1 study (NCT06549595), a Phase III randomized trial evaluating surovatamig plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma (FL) and high tumor burden. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
SOUNDTRACK-F1 is another trials-in-progress abstract using the same drug, surovatamig, this time in patients with treatment-naive high-tumor burden follicular lymphoma. There was a safety run-in phase which included about 40 patients who all received surovatamig, and now the study is into a randomization between 1:1:1. There’s an arm with surovatamig followed by maintenance...
SOUNDTRACK-F1 is another trials-in-progress abstract using the same drug, surovatamig, this time in patients with treatment-naive high-tumor burden follicular lymphoma. There was a safety run-in phase which included about 40 patients who all received surovatamig, and now the study is into a randomization between 1:1:1. There’s an arm with surovatamig followed by maintenance. There’s an arm with surovatamig with no maintenance. And then the third arm is the control arm, which is chemoimmunotherapy alone, rituximab plus a physician’s choice of CHOP, CVP or bendamustine. Primary endpoint for this trial is progression-free survival, and it’s a global phase three study with a primary endpoint of PFS for which enrollment is ongoing, and yeah, we’re excited to see the results.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
